常山药业(300255) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥319,240,456.34, a decrease of 50.68% compared to the previous quarter, and a 36.47% decline year-over-year[9]. - The net profit attributable to shareholders was -¥232,452,300.57, representing a significant decrease of 9,293.93% compared to the previous quarter, and a 677.10% decline year-over-year[9]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥233,760,696.77, a decrease of 67,176.14% quarter-over-quarter, and a 740.70% decline year-over-year[9]. - The company's operating revenue decreased by 36.47% compared to the same period last year, primarily due to a decline in heparin raw material sales and a drop in the unit price of low molecular weight heparin preparations[39]. - Total operating revenue for the current period is approximately $1.14 billion, a decrease of about 36.5% compared to the previous period's $1.79 billion[52]. - Operating profit for the current period is reported as a loss of approximately $406.28 million, compared to a profit of $86.21 million in the previous period[52]. - The net profit attributable to shareholders of the parent company was -388,330,627.87 CNY, compared to a profit of 67,289,460.52 CNY in the previous period, indicating a significant decline[53]. - The total comprehensive income for the period was -395,868,638.95 CNY, compared to 56,628,177.82 CNY in the previous period[53]. Assets and Liabilities - The company's total assets at the end of the reporting period were ¥5,429,369,030.48, down 10.05% from the end of the previous year[9]. - The equity attributable to shareholders decreased to ¥2,664,226,271.21, a decline of 12.88% compared to the end of the previous year[9]. - The total liabilities amount to approximately $2.78 billion, down from $2.98 billion in the previous period, indicating a reduction of about 6.9%[51]. - Non-current liabilities total approximately $936.40 million, a decrease of about 21.5% from $1.19 billion in the previous period[51]. - Accounts payable decreased by 43.28% compared to the beginning of the year, primarily due to a reduction in procurement payments[37]. - Non-current liabilities due within one year increased by 108.15% compared to the beginning of the year, mainly due to the transfer of long-term borrowings to current liabilities[37]. Cash Flow - The net cash flow from operating activities increased by 32.86% year-over-year, primarily due to reduced cash payments for goods and services[19]. - The company reported cash inflows from operating activities totaling 1,393,981,069.62 CNY, down from 1,931,714,181.30 CNY in the previous period[55]. - Cash outflows from operating activities were 1,517,341,555.87 CNY, compared to 2,115,437,263.56 CNY in the previous period[55]. - The company incurred a cash outflow of 192,500,679.35 CNY from financing activities, an improvement from -314,849,043.65 CNY in the previous period[55]. - The company received cash from borrowings amounting to 1,189,326,113.18 CNY, down from 1,859,945,742.67 CNY in the previous period[56]. Expenses - The company's sales expenses decreased by 30.34% year-over-year, mainly due to reduced marketing expenses[16]. - Research and development expenses for the current period amount to approximately $100.56 million, a decrease of about 12.9% from $115.42 million in the previous period[52]. - Tax expenses for the current period are approximately $17.34 million, compared to $15.89 million in the previous period, an increase of about 9.1%[52]. Other Financial Metrics - Other income increased by 86.16% year-on-year, mainly due to an increase in government subsidies received during the period[40]. - The company recorded other income of approximately $14.69 million, an increase from $7.89 million in the previous period[52]. - The company reported a decrease in cash received from sales of goods and services to 1,318,521,579.40 CNY from 1,841,464,617.92 CNY in the previous period[55]. - The company's cash and cash equivalents net increase decreased by 329.39% year-over-year, primarily due to reduced cash inflow from financing activities[20]. - Cash and cash equivalents at the end of the period decreased to 278,708,793.73 CNY from 384,734,470.51 CNY in the previous period[56]. Shareholder Information - The company plans to unlock 25% of the shares held by executives annually during their tenure, with specific unlock dates set for June 29, 2025, for certain executives[47]. - The total number of restricted shares at the end of the period was 3,162,332, with 191,250 shares released during the current period[46].